| For: | Juneja D, Nasa P, Jain R, Singh O. Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports. World J Diabetes 2023; 14(8): 1314-1322 [PMID: 37664476 DOI: 10.4239/wjd.v14.i8.1314] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v14/i8/1314.htm |
| Number | Citing Articles |
| 1 |
Glenda Elaine Bilder, Patricia Brown-O’Hara. Drug Use in the Older Adult. 2025; doi: 10.1007/978-3-031-84831-5_3
|
| 2 |
Dimitra Stathi, Ketan K. Dhatariya, Omar G. Mustafa. Management of diabetes‐related hyperglycaemic emergencies in advanced chronic kidney disease: Review of the literature and recommendations. Diabetic Medicine 2025; 42(2) doi: 10.1111/dme.15405
|
| 3 |
Andreas Holstein, Jonas A. Linck, Johann Christoph Blaue, Rainer Högel, David J. F. Holstein. Successful renal replacement therapy of extreme ertugliflozin and alcohol induced euglycaemic ketoacidosis. Acta Diabetologica 2024; 62(3) doi: 10.1007/s00592-024-02417-8
|
| 4 |
Eslam Abady, Panos I. Tamvakologos, Marina Ramzy Mourid, Salma Tamer Abdelrahman, Mayam Mohamed Aziz, Shree Rath, Lauren A. Carr, Mohammed Alsabri. A narrative review of the diabetic ketoacidosis and hyperosmolar hyperglycemic state overlap syndrome. International Journal of Emergency Medicine 2025; 18(1) doi: 10.1186/s12245-025-01078-w
|
| 5 |
Paul S. Pagel, Dustin Hang, Julie K. Freed, George J. Crystal. Advances in Cardiovascular Pharmacotherapy. IV. Sodium-Glucose Cotransporter Type 2 Inhibitors, Part 2: Mechanisms for Myocardial Protection, Adverse Effects, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia 2025; 39(11) doi: 10.1053/j.jvca.2025.06.015
|
| 6 |
Rupak Chatterjee, Rajat K Goswami, Atanu Chandra, Shambo S Samajdar, Shatavisa Mukherjee, Nandini Chatterjee, Jyotirmoy Pal, Sarmishtha Mukhopadhyay. Euglycemic Diabetic Ketoacidosis in Patients on Sodium–Glucose Cotransporter-2 Inhibitors: A Preliminary Observation from Eastern India. Bengal Physician Journal 2025; 12(4) doi: 10.5005/jp-journals-10070-8106
|
| 7 |
Ravi Shukla, Puja Shrestha, Binod Khanal, Bipal Regmi. Euglycemic Diabetic Ketoacidosis: Clinical Suspicion and Diagnosis. Clinical Medicine Insights: Endocrinology and Diabetes 2026; 19 doi: 10.1177/11795514261431390
|
| 8 |
Elsayed Balbaa, Ahmed Farid Gadelmawla, Ahmed Ibrahim, AlMothana Manasrah, Ahmed Elbataa, Abdalhakim Shubietah, Mohamed S. Elgendy, Ahmed Sobhy, Ahmed Mansour, Ameer Awashra, Nourhan N. Elguindy, Mohammad Bazzazeh, Abdelhamid Ben‐Selma. Renal Protection at a Metabolic Cost: A Systematic Review and Meta‐Analysis of Perioperative Use of Sodium–Glucose Cotransporter 2 Inhibitors. Endocrinology, Diabetes & Metabolism 2026; 9(2) doi: 10.1002/edm2.70180
|
| 9 |
L. I. P. Snel, X. Li, F. Jamaludin, S. E. Siegelaar, F. Holleman, T. M. Vriesendorp, J. H. DeVries, J. B. L. Hoekstra, B. Preckel, D. H. van Raalte, J. Hermanides, A. H. Hulst. A Systematic Review and Expert Evaluation of Perioperative SGLT2 Inhibitor‐Associated Ketoacidosis Case Reports. Acta Anaesthesiologica Scandinavica 2026; 70(6) doi: 10.1111/aas.70254
|
| 10 |
Lulu Chu, Zhenhua Xi, Runzhi Ma, Weiliang Shi, Guoshen Yu. Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report. BMC Neurology 2025; 25(1) doi: 10.1186/s12883-025-04027-5
|
| 11 |
Johannes Nienhaus, Theresa Tenge, Sophia Riesemann, Detlef Kindgen-Milles, Giovanna Lurati Buse, René MʼPembele, Sebastian Roth. Natrium-Glukose-Co-Transporter-2 (SGLT-2)-Hemmer in der perioperativen Medizin. Die Anaesthesiologie 2025; 74(10) doi: 10.1007/s00101-025-01580-z
|
| 12 |
Luminita-Georgeta Confederat, Alin-Constantin Pînzariu, Ionela Lacramioara Serban, Mihaela-Iustina Condurache, Oana-Maria Dragostin. SGLT2 Inhibitors Between Benefits and Euglycemic Ketoacidosis: A Concise Review. International Journal of Molecular Sciences 2026; 27(12) doi: 10.3390/ijms27125224
|
| 13 |
Jing Cai, Tiantian Fu, Cuixia Tan. Case Report: Early-onset euglycemic diabetic ketoacidosis following henagliflozin initiation in a treatment-naive patient. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1882272
|
| 14 |
Jose Guillermo Cabanillas-López, Luis Ángel Rodriguez-Chávez, Melissa Ysabel Romero-Diaz, Christian Alberto Vargas-Machuca Carranza. Cetoacidosis euglucémica por empagliflozina: Reporte de un caso. Medicina Clínica Práctica 2026; 9(2) doi: 10.1016/j.mcpsp.2026.100535
|
| 15 |
Naina Mohamed Pakkir Maideen, Sulthan Al Rashid, Rajkapoor Balasubramanian, Deepika Vishwanathan, Arun Shanmugam. Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: Epidemiology, Mechanisms, Diagnosis, Prevention, and Future Perspectives. SN Comprehensive Clinical Medicine 2026; 8(1) doi: 10.1007/s42399-026-02540-3
|
| 16 |
Swapnil Khare, Mihail Zilbermint, Rajesh Garg, Viral N. Shah. Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus Report. Endocrine Practice 2024; 30(9) doi: 10.1016/j.eprac.2024.06.011
|
| 17 |
Japleen Kaur, Ashima Dogra, Anna Haymov. When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor–Induced Euglycemic Diabetic Ketoacidosis. Cureus 2025; doi: 10.7759/cureus.95681
|
| 18 |
Teodora Mateoc, Andrei-Luca Dumitrascu, Corina Flangea, Daniela Puscasiu, Tania Vlad, Roxana Popescu, Cristina Marina, Daliborca-Cristina Vlad. SGLT2 Inhibitors: From Structure–Effect Relationship to Pharmacological Response. International Journal of Molecular Sciences 2025; 26(14) doi: 10.3390/ijms26146937
|
| 19 |
Caroline G. P. Roberts, Shaminie J. Athinarayanan, Robert E. Ratner, Guillermo E. Umpierrez. Illnesses associated with ketosis including diabetic ketoacidosis during very low carbohydrate and ketogenic diets. Diabetes, Obesity and Metabolism 2025; 27(5) doi: 10.1111/dom.16252
|
| 20 |
José Paz-Ibarra, Juan Eduardo Quiroz-Aldave, María del Carmen Durand-Vásquez, Luis Alberto Concepción-Urteaga, Rommy Díaz Quispe, Marcio José Concepción-Zavaleta. Primer caso reportado en Perú de cetoacidosis euglicémica por inhibidor del cotransportador de sodio glucosa tipo 2. Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo 2025; 18(1) doi: 10.35434/rcmhnaaa.2025.181.2677
|
| 21 |
Natalia G. Vallianou, Dimitris C. Kounatidis, Eleni V. Geladari, Angelos Evangelopoulos, Vasileios Kaldis, Theodora Stratigou, Apostolos A. Evangelopoulos, Irene Karampela, Maria Dalamaga. Climate Change, Air Pollution and the Global Obesity Syndemic: a Review of Current Evidence. Current Obesity Reports 2025; 14(1) doi: 10.1007/s13679-025-00671-7
|
| 22 |
Andrijana Koceva, Nika Aleksandra Kravos Tramšek. From Sweet to Sour: SGLT-2-Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. Journal of Personalized Medicine 2024; 14(7) doi: 10.3390/jpm14070665
|
| 23 |
Hiroshi Bando, Michael Wood, Koji Ebe. Expanding Applications of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) with Attention to Euglycemic Ketoacidosis (Eka) for No Diabetic History. Diabetes Research: Open Access 2025; 6(1) doi: 10.36502/2025/droa.6191
|
| 24 |
Rohini Garg, Nikhil Sood, Ojas Bansal, Abhinav Hoskote. Euglycemic Ketoacidosis Associated with SGLT-2 Inhibitors in Non-diabetic Patients—A Narrative Review. Journal of General Internal Medicine 2025; 40(2) doi: 10.1007/s11606-024-09073-2
|
| 25 |
Mahesh Ramanan, Elif Ekinci. Oh's Intensive Care Manual. 2026; doi: 10.1016/B978-0-443-11611-7.00068-2
|
| 26 |
Alessandro Rossi, Chiara Simeoli, Rosario Pivonello, Mariacarolina Salerno, Carmen Rosano, Barbara Brunetti, Pietro Strisciuglio, Annamaria Colao, Giancarlo Parenti, Daniela Melis, Terry G.J. Derks. Endocrine involvement in hepatic glycogen storage diseases: pathophysiology and implications for care. Reviews in Endocrine and Metabolic Disorders 2024; 25(4) doi: 10.1007/s11154-024-09880-2
|
| 27 |
Selin Genc, Bahri Evren, Onur Selcuk Yigit, Ibrahim Sahin, Ramazan Dayanan, Aleksandra Klisic, Ayse Erturk, Filiz Mercantepe. Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors. Pharmaceuticals 2024; 17(11) doi: 10.3390/ph17111553
|
| 28 |
Nagendra K Singh, Akash Kumar Singh, Bijay Patni, Prabhat Agarwal, Manohar Kathige Nageshappa, Manish Kumar Prasad, Meena Chhabra, Noni G Singha, Minakshisundaram Shunmugavelu, Arvind Gupta, Sanjeev Phatak, Mangesh Tiwaskar, Sanjay Kalra, Manash Pratim Baruah, Thamburaj Anthuvan, Abhijit Pednekar, Ashish Prasad, Smriti Gadia. Consensus to Reduce Withdrawal and Improve Adherence with SGLT2i: Consensus TWO SGLT2i Adherence Group. Journal of The Association of Physicians of India 2025; 73(4) doi: 10.59556/japi.73.0887
|
| 29 |
Afif Nakhleh, Areen Othman, Amin Masri, Moshe Zloczower, Sagit Zolotov, Naim Shehadeh. Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study. Biomedicines 2023; 11(10) doi: 10.3390/biomedicines11102689
|
| 30 |
Paul A. Stewart, Claire C. Nestor, Cillian Clancy, Michael G. Irwin. The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review. Anaesthesia 2025; 80(1) doi: 10.1111/anae.16461
|